An Open-label Phase 1 Study of ASP4396 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
Latest Information Update: 22 Dec 2024
At a glance
- Drugs ASP 4396 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Astellas Pharma
- 26 Apr 2024 Status changed from not yet recruiting to recruiting.
- 18 Apr 2024 New trial record